Zobrazeno 41 - 50
of 208
pro vyhledávání: '"Andrew Haydon"'
Autor:
Wanxing Chai-Ho, Jenny H. Lee, Ignacio Melero, Andrew Haydon, Nikhil I. Khushalani, Jose Lutzky, Andrew F. Hill, Gregory A. Daniels, Muhammad Alamgeer, Ragini R. Kudchadkar, Dimitrios Colevas, Ann Silk, Piyush Sheladia, Daniel Brungs, Shui He, Praveen K. Bommareddy, Frances A. Collichio, Samantha Bowyer, Céleste Lebbé, Michael R. Migden, Danny Rischin, Jean-jaques Grob, Matthew G. Fury, Claudia Andreu-Vieyra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients with the disease despite approval of the anti-PD1 antibodies cemiplimab and pembrolizumab.1 2 RP1 is an oncolytic virus (HSV-1
Publikováno v:
Clinical Nuclear Medicine. 46:e329-e331
We report an unusual case of a 59-year-old man with recurrent right ear melanoma resulting in perineural spread to the right greater auricular nerve. Direct perineural spread to the greater auricular nerve is not commonly reported in melanoma. Our ca
Autor:
Prachi Bhave, Andrew Haydon
Publikováno v:
Australasian Journal of Dermatology. 61:203-209
Stage III melanoma involves regional lymph nodes and/or in-transit or satellite disease, without spread to distant metastatic sites. Stage IIIA melanoma includes a T1a-T2a primary lesion with N1a or N2a nodal involvement, whilst stage IIID melanoma i
Autor:
Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
Publikováno v:
Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
PURPOSE We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of
Autor:
Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
Publikováno v:
Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association
Importance: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.Objective: To investigate the association between irAEs and recurrence-free survival (RFS) in the d
Autor:
Adnan Nagrial, David Goldstein, Niall C. Tebbutt, Bert Vogelstein, Joshua D. Cohen, Lu Li, Andrew Haydon, Kenneth W. Kinzler, Koen Simons, Peter Gibbs, Jeanne Tie, Cristian Tomasetti, D W M Tai, Prasad Cooray, Nick Papadopoulos, C L Wolfgang, Matthew Burge, Lara Lipton, Belinda Lee, Mehrdad Nikfarjam, Ammar A. Javed, Marion Harris, Benjamin N. J. Thomson, A M Lennon, B. Lawrence
Publikováno v:
Annals of Oncology. 30:1472-1478
In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to info
Autor:
Harindra Jayasekara, Roger L. Milne, Pietro Ferrari, John L. Hopper, Yi Yang, Robert J. MacInnis, Graham G. Giles, Hazel M. Mitchell, Andrew Haydon, Allison M. Hodge, Robin Room, Dallas R. English, Marc J. Gunter, Elio Riboli
Publikováno v:
International Journal of Epidemiology. 50
Background Alcohol consumption is causally linked to several cancer sites but the evidence for stomach cancer is still inconclusive. We aimed to quantify the association between alcohol intake and risk of stomach cancer, including subtypes. Methods W
Autor:
John Zalcberg, John J McNeil, Jessica E. Lockery, Anne Murray, Suzanne G Orchard, Galina Polehkina, Rory Wolfe, Mark Nelson, Robyn L. Woods, Peter Gibbs, Brenda Kirpach, Christopher M. Reid, Andrew Haydon
Publikováno v:
International Journal of Epidemiology. 50
Background The ASPirin in Reducing Events in the Elderly (ASPREE) study randomised healthy older individuals to 100mg aspirin or placebo, with clinical outcomes and disability-free survival endpoints. Detailed baseline data provides a rare opportunit
Autor:
Ines Pires da Silva, Alexander M. Menzies, Andrew Haydon, Patricio Serra-Bellver, Céleste Lebbé, Irene L.M. Reijers, James R. Patrinely, Olivier Michielin, Shahneen Sandhu, Paul Lorigan, Douglas B. Johnson, Camille L. Gerard, Joanna Mangana, Oliver Klein, Paolo A. Ascierto, Serigne Lo, Tasnia Ahmed, Allison Betof Warner, Lisa Zimmer, Georgina V. Long, Clara Allayous, Claudia Trojaniello, Matteo S. Carlino
Publikováno v:
The Lancet. Oncology. 22(8)
Weitere Nicht-UDE Autoren sind nicht genannt.
Autor:
B. Mark Smithers, Andrew Haydon, Rachel Roberts-Thomson, Richard C. W. Martin, Robyn P. M. Saw, John F. Thompson, Victoria Atkinson, David E. Gyorki
Publikováno v:
ANZ journal of surgeryREFERENCES. 91
Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care p